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Chronic ACTH excess leads to chronic cortisol excess, without escape phenomenon, 
resulting in Cushing’s syndrome. Excess adrenal androgens also occur: in females, 
they will overcompensate the gonadotrophic loss, inducing high testosterone; in males, 
they will not compensate it, inducing low testosterone. Chronic ACTH excess leads to 
chronic adrenal mineralocorticoid excess and low aldosterone levels: after an acute rise, 
aldosterone plasma levels resume low values after a few days when ACTH is prolonged. 
Two other mineralocorticoids in man, cortisol and 11 deoxycorticosterone (DOC), at 
the zona fasciculata, will not escape the long-term effect of chronic ACTH excess and 
their secretion rates will remain elevated in parallel. Over all, the concomitant rise in 
cortisol and 11 DOC will more than compensate the loss of aldosterone, and eventually 
create a state of chronic mineralocorticoid excess, best evidenced by the accompanying 
suppression of the renin plasma levels, a further contribution to the suppression of aldo-
sterone secretion. Prolonged in vivo stimulation with ACTH leads to an increase in total 
adrenal protein and RNA synthesis. Cell proliferation is indicated by an increase in total 
DNA the resulting adrenocortical hyperplasia participates in the amplified response of the 
chronically stimulated gland, and the weight of each gland can be greatly increased. The 
growth-stimulatory effect of ACTH in vivo most likely proceeds through the activation 
of a local and complex network of autocrine growth factors and their own receptors; 
a number of compounds, including non-ACTH proopiomelanocortin peptides such as 
γ3-MSH, have been shown to exert some adrenocortical growth effect.
Keywords: adrenal, ACTH excess, Cushing’s syndrome, cortisol, androgens, mineralocorticoids, adrenal cortex 
growth
inTRODUCTiOn
The pituitary–adrenal axis is a central actor in Endocrinology. Through it, the fine tuning of cor-
ticosteroids secretion is maintained, from fetal to adult life, under basal and stressful conditions, 
with immediate and/or long-term consequences. Altered ACTH secretion induces catastrophic 
clinical situations: adrenal insufficiency on the one hand, Cushing’s syndrome on the other hand. 
Both are debilitating conditions that severely alter the quality of life, create multiple complications, 
and, ultimately may lead to premature death. Besides ACTH-dependent Cushing’s syndrome, there 
are many situations where ACTH is chronically oversecreted. This review will examine the effects of 
chronic ACTH excess on adrenal cortex in man, and concentrate on steroid secretion and adrenal 
cortex growth.
Rare and particular situations will also be addressed.
TAble 1 | Conditions with chronic ACTH excess in man.
normal adrenal cortexa
ACTH/Cortrosyn administration to normal volunteers
ACTH-dependent Cushing’s syndrome
Cushing’s disease; ectopic ACTH secretion syndrome
General resistance to glucocorticoids
Abnormal adrenal cortex: disorders of steroid synthesisb
Congenital adrenal hyperplasia
21 Hydroxylase-, 11 hydroxylase-, 17 hydroxylase deficiencies
Inhibitors of adrenal steroidogenesis
Metyrapone, ketoconazole, etomidate, aminoglutethimide, LCI699
Abnormal adrenal cortex: «missing» adrenal glands
Acquired destruction
Addison’s disease
Bilateral adrenalectomy
Adrenolytic drugs (o,p′DDD)
Congenital developmental defects
aModel to study both the functional and anatomical effects of chronic ACTH excess.
bModel to study the anatomical effects of chronic ACTH excess.
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THe vARiOUS SiTUATiOnS in MAn  
wiTH CHROniC ACTH eXCeSS
The many situations that are associated with chronic ACTH excess 
in man are presented in Table 1. Depending on the «quality» of 
the original adrenal cortex they can be artificially distinguished 
in three different groups.
There Are Three Situations where the 
Adrenal Cortex is Originally, Functionally, 
and Anatomically normal
 – Healthy volunteers administered with exogenous ACTH or its 
synthetic analog Cortrosyn (ACTH1–24).
 – Patients with ACTH-dependent Cushing’s syndrome, either 
Cushing’s disease or the ectopic ACTH secretion syndrome. 
Excess ACTH is chronically produced by a pituitary or a non-
pituitary tumor and acts on a basically normal adrenal cortex.
 – Patients with the syndrome of general resistance to 
glucocorticoids.
These three situations allow measuring the effects of chronic 
ACTH excess on both corticosteroid secretions and adrenal 
cortex growth.
There Are Two Situations where the 
Adrenal Cortex Has, Congenital or 
Acquired, intrinsic Steroidogenic Defects
 – The various types of congenital adrenal hyperplasias (CAHs) 
associated with altered cortisol synthesis.
 – Treatment of ACTH-dependent Cushing’s syndrome with 
anticortisolic drugs that inhibit steroidogenesis (metyrapone, 
ketoconazole, etomidate, aminoglutethimide, LCI699).
In both situations, chronic ACTH excess is an adapted 
response to chronic cortisol deprivation. They preclude studying 
the effects of chronic ACTH excess on corticosteroid secretions. 
Still the effects on adrenocortical growth can be evaluated in a 
pertinent fashion.
in the last Situations, the Adrenal Cortex 
is Simply—And Anatomically—Missing or 
Compromised
 – Bilateral adrenalectomy, usually for ACTH-dependent 
Cushing’s syndrome.
 – Adrenolytic treatments (o,p′DDD) of ACTH-dependent 
Cushing’s syndrome.
 – Acquired adrenal destructions (infections, hemorrhagies, 
autoimmune, bilateral metastases…).
 – Congenital developmental defects (genetic syndromes).
Evidently, none of these situations help to study the «adre-
nal» effects of chronic ACTH excess. They would be, however, 
adapted to study the non-adrenal effects of chronic ACTH—and 
proopiomelanocortin (POMC)-related peptides excess. Indeed, 
by opposition with the sole situation where ACTH itself—or its 
synthetic analog Cortrosyn—are exogenously administered to 
healthy volunteers, all other situations with chronic excess of 
endogenous ACTH are accompanied by parallel excess of other 
non-ACTH POMC-derived peptides.
CHROniC ACTH eXCeSS in MAn  
AnD CORTiCOSTeROiD SeCReTiOn
Cortisol
Chronic ACTH Excess Leads to Chronic Cortisol 
Excess
Experiments in healthy volunteers, more than half a century ago, 
have shown the effects of repeated ACTH administrations (1, 2).
 – When the same dose of ACTH is exogenously administered 
daily in man, a stepwise increase in daily cortisol secretion is 
observed over the days [see Figure 8 in Ref. (1)].
 – This «amplifying» phenomenon has now a molecular explana-
tion: adrenocortical cells exposed to ACTH in vitro acquire 
an increased number of ACTH receptors (MC2R) and an 
increased rate of protein Gs expression (3–6).
 – Through the cAMP pathway the binding of ACTH and the 
transducing apparatus are both amplified, explaining the 
higher sensitivity and the greater response potential of chroni-
cally stimulated cells.
 – No escape phenomenon is observed, although the cortisol 
oversecretion tends to plateau after several days.
 – Over a wide range, the cortisol response is proportional to the 
dose of administered ACTH.
In patients with ACTH-dependent Cushing’s syndrome, 
chronic excess of endogenous ACTH also leads to chronic 
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cortisol excess. Interestingly in many patients with Cushing’s 
disease, cortisol excess is associated with «normal» ACTH 
plasma values compared with those seen in the morning in 
normal subjects (7, 8). These values are considered «abnor-
mally» normal or «inappropriate» in face of the hypercorti-
solism that should normally totally suppress ACTH secretion. 
Furthermore, these levels remain constant over the day, with 
no circadian variation, and ACTH acts on hyperresponsive 
adrenocortical cells; indeed, acute ACTH stimulation of the 
hyperplastic adrenals in Cushing’s disease patients triggers 
a much higher and more lasting response than would be 
observed in normal subjects given the same dose [see Figure 2 
in Ref. (2)].
Chronic ACTH excess in case of non-pituitary tumors (the 
ectopic ACTH secretion syndrome) has the exact same conse-
quences on cortisol secretion. Because ACTH plasma levels are 
often higher in these patients, they also have—in general—higher 
cortisol oversecretion (8).
In the syndrome of general resistance to cortisol, the glu-
cocorticoid receptor type 2 is mutated with a loss of function. 
It is an autosomal dominant familial disease (9–11). All cells 
and tissues have lost their normal sensitivity to cortisol. At the 
hypothalamic–pituitary level, it is felt as an apparent lack of 
cortisol, which—naturally—induces an adapted response with 
chronic increase in ACTH secretion (12). This natural human 
situation offers a privileged model to observe the response of 
a perfectly normal adrenal cortex to chronic ACTH excess: 
unsurprisingly chronic cortisol excess is observed, but without 
the clinical features of Cushing’s syndrome. Together with 
cortisol, other ACTH-dependent corticosteroids, androgens 
dehydroepiandrosterone (DHEA), and mineralocorticoids 
deoxycorticosterone (DOC) are oversecreted by the zona fas-
ciculata (see further).
A state of chronic and acquired general resistance to cor-
tisol can be artificially created in Cushing’s disease patients 
chronically treated with RU486 (Mifepristone). The drug is 
an antagonist to the glucocorticoid receptor type 2, the acute 
administration of which triggers an immediate pituitary ACTH 
retort in normal subjects (13, 14). As expected, under long-term 
RU486 administration some clinical peripheral features of the 
Cushing’s syndrome are ameliorated such as hyperglycemia 
(15); as expected also, in the patients with Cushing’s disease, 
the hypothalamic–pituitary–adrenal axis is stimulated (by the 
“apparent” cortisol deprivation) and ACTH is acutely and/
or chronically increased further with plasma levels raising 
up ca. three times above their baseline initial values (16, 17). 
In the SEISMIC study, several patients developed high blood 
pressure, edema, and hypokelmia suggestive of a state of 
chronic hypermineralocorticism (17). All ACTH-dependent 
corticosteroids presumably increase in parallel: cortisol, the 
clinical impact of which remains blunted at the glucocorticoid 
receptor by the drug; but also adrenal androgens and DOC, the 
actions of which are not opposed at their respective androgen 
and mineralocorticoid receptors (for both DOC and cortisol) 
and which may thus induce serious clinical features: possibly 
hyperandogenism in women; hypertension and hypokalemia in 
both sexes (18).
Adrenocortical Androgens
Chronic ACTH Excess Leads to Chronic Adrenal 
Androgens Excess with Contrasted Impacts in 
Females and Males
Adrenal androgens are produced by the zona fasciculata/reticu-
laris, and—as cortisol—are under the same—and dominant 
if not exclusive—control of ACTH and the cAMP pathway. 
Acute administration to healthy volunteers induces abrupt 
increase in circulating adrenal androgens (19). The situation 
has been particularly studied in Cushing’s disease patients. The 
specific adrenal androgen DHEA sulfate (DHEAS) is chronically 
increased both in males and females (20). Thus DHEA, DHEAS, 
and Δ-4-androstenedione are elevated in Cushing’s disease 
patients (21–23). Yet, the impact of chronic ACTH excess upon 
the overall androgenic status is contrasted between females and 
males:
 – In both females and males, chronic excess of androgens, 
and cortisol, both lead to suppressed gonadotroph function 
directly at the hypothalamic–pituitary levels.
 – In females, because the pituitary gonadotrophic function nor-
mally accounts for only half of the total circulating androgens, 
the excess adrenal androgens will eventually overcompensate 
the gonadotrophic loss and induce an overall excess of 
circulating androgens: their peripheral transformation to 
testosterone and dihydrotestosterone may lead to a moderate 
state of androgen excess in females with its clinical impact: 
hirsutism, infertility [see Figure 3 in Ref. (22)].
 – In males, because the pituitary gonadotrophic/gonadal func-
tion normally accounts for the vast majority of circulating 
androgens (ca. 90%), the excess of adrenal androgens will 
not compensate that which has been lost due to the cortisol-
induced suppression of the gonadotrophic/gonadal function. 
The overall circulating androgens will eventually be abnor-
mally low (testosterone), with a clinical impact: decreased 
sexual activity, infertility (24).
In a way similar to that observed with cortisol, chronic 
increase in adrenal androgens will be observed in other situations 
with chronic ACTH excess such as the ectopic ACTH secretion 
syndrome, and the general resistance to glucocorticoids. In the 
latter situation, as evoked earlier, excess androgens in females 
may be the dominant symptom that should alert on the diagnosis 
in the absence of «Cushing’s» features; it may provoke precocious 
puberty in children (12).
In patients with Cushing’s disease treated with the antigluco-
corticoid RU486, the inescapable rise in ACTH secretion will—
theoretically—increase further the state of hyperandrogenism in 
females and this should be a major drawback for the use of this 
compound …. Surprisingly, there is no report on the clinical or 
hormonal androgen status of women in the SEISMIC study (17).
Dissociation between cortisol and adrenal androgens is 
observed, however, in the particular situation of patients resum-
ing normal corticotroph function after long-term ACTH excess. 
After successful pituitary surgery in Cushing’s disease patients, 
DHEAS remains suppressed for months or years after plasma 
cortisol has normalized (21).
FigURe 1 | Schematic overview of the comparative effects of normal 
and prolonged ACTH excess in man on adrenal cortical steroids at 
the zona glomerulosa and the zona fasciculata/reticularis.
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Mineralocorticoids
Chronic ACTH Excess Leads to Chronic Adrenal 
Mineralocorticoid Excess and Low Aldosterone 
Levels
It has long been known that acute ACTH administration to man 
leads to immediate aldosterone secretion; yet this effect is only 
transient and is not maintained when ACTH is prolonged over 
periods of time, and aldosterone plasma levels resume low values 
after a few days (25, 26).
Yet this “escape” phenomenon on aldosterone will not prevent 
the establishment of a state of chronic mineralocorticoid excess, 
for two reasons:
 – This “escape” will only concern aldosterone, at the zona glo-
merulosa. Its exact mechanism is not entirely understood: it 
is suggested that increased concentrations of cortisol in the 
adrenal cortex directly inactivates the last steps of aldosterone 
synthesis in the ZG (27); there is also evidence that initial ZG 
cells undergo a differentiation process toward cortisol produc-
ing cells (28).
 – Two other mineralocorticoids in man, cortisol and 11 DOC, 
at the zona fasciculata, will not escape the long-term effect of 
chronic ACTH excess and their secretion rates will remain 
elevated in parallel (29).
Over all, the concomitant rise in cortisol and DOC, even 
though each of these molecules is intrinsically less potent than 
aldosterone at the mineralocorticoid receptor, will more than 
compensate the loss of aldosterone, and eventually create a 
state of chronic mineralocorticoid excess, best evidenced by the 
accompanying suppression of the renin plasma levels, a further—
if not exclusive—contribution to the suppression of aldosterone 
secretion (30). This general mineralocorticoid effect is in cor-
relation with the level of ACTH excess: its clinical consequences 
(high blood pressure, hypokalemic alkalosis) are more frequent 
in patients with the ectopic ACTH secretion syndrome than in 
those with Cushing’s disease (31).
As expected, patients with the syndrome of general resistance 
to glucocorticoids have parallel increases in cortisol and DOC, 
and hypokalemic hypertension may be another—sometime pre-
dominant—clinical presentation in these patients, as reported in 
the first published cases (9).
These complications may also occur in patients with Cushing’s 
disease treated by RU486 (Mifepristone). The drug induces a 
further increase in cortisol and probably DOC (this latter steroid 
rarely if ever measured in these patients!), which both can inter-
act, without any opposition, at the mineralocorticoid receptor 
(18), and see Figure 1.
CHROniC ACTH eXCeSS in MAn  
AnD ADRenAl CORTeX gROwTH
The central role of ACTH on the adrenal cortex trophicity 
has long been known. Hypophysectomy results in adrenal 
cortex atrophy that is restored by the sole administration of 
ACTH (32). Thus, in vivo, ACTH is the predominant if not the 
exclusive trophic factor for the adrenals. More recently, various 
animal models, which eliminate ACTH or its receptor (MC2R) 
in transgenic mice, have confirmed the central role of ACTH 
to maintain normal adrenal cortex growth (33–35). Prolonged 
in  vivo stimulation with chronic ACTH administration or 
oversecretion eventually leads to an increase in total adrenal 
protein and RNA synthesis. Cell proliferation is indicated by an 
increase in total DNA (32) the resulting adrenocortical hyper-
plasia participates in the amplified response of the chronically 
stimulated gland, and the weight of each gland can be greatly 
increased.
The exact mechanism whereby ACTH promotes adrenocorti-
cal growth still is complex and remains partially understood, 
since in vitro studies show a paradoxical negative effect of ACTH 
on adrenocortical cell proliferation (36) The growth-stimulatory 
effect of ACTH in vivo most likely proceeds through the activation 
of a local and complex network of autocrine growth factors and 
their own receptors; a number substances, including non-ACTH 
POMC peptides such as γ3-MSH, have been shown to exert some 
adrenocortical growth effect (28).
In ACTH-dependent Cushing’s syndrome, chronic ACTH 
excess leads to bilateral adrenal hyperplasia: both adrenals are 
enlarged, their weight is increased in comparison with normal 
glands, and the histological appearance shows diffuse widening 
of the fasciculata/reticularis zona (Figure 2). This hyperplasia is 
typically homogeneous and rather symmetrical. In some cases 
however, it may be asymmetrical, and/or one or the two glands 
may bear nodular zones or authentic nodules embedded within 
the diffuse hyperplasia. Today, CT-Scan allows to see the adrenal 
hyperplasia in vivo in patients with ACTH-dependent Cushing’s 
syndrome, and to observe its fate after the suppression of ACTH, 
that is after successful pituitary surgery: the two enlarged glands 
and the nodules progressively shrink and can even become 
atrophic until normal ACTH secretion is spontaneously restored, 
which may take months or years (37, 38). In parallel to these 
anatomical changes, baseline cortisol and its response to the acute 
stimulation by ACTH is suppressed, and progressively resume 
FigURe 3 | CT-scan images of enlarged and nodular adrenal glands in 
a patient with 21 hydroxylase deficiency. Regression under ACTH 
suppression by large doses of glucocorticoids.
FigURe 2 | Comparing the macroscopic aspect of normal adrenals 
and those of a Cushing’s disease patient.
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over months or years. As already mentioned, cortisol response is 
restored more rapidly than androgen response.
A rather similar presentation is observed in patients with 
CAH: both glands are enlarged, and become smaller under 
glucocorticoid administration (Figure 3).
Some studies seem to demonstrate that chronic ACTH excess 
also favors the appearance of adrenocortical nodules, and it has 
been suggested that some of them ultimately become autono-
mous (i.e., ACTH-independent). Yet, it is common observation 
that suppression of chronic ACTH excess, in Cushing’s or CAH 
patients, reduces both the hyperplastic and nodular parts of the 
enlarged glands (Figure 3).
Interestingly, the growth promoting effect of chronic ACTH 
excess can be exerted also at distance, on adrenal rests:
 – Testicular adrenal rests may develop as local tumors which 
impinge the normal spermatogenesis, and may become cause 
of infertility in poorly controlled male patients with CAH 
(39). There is some evidence that lowering ACTH plasma 
levels may shrink these tumors which, in contrast with the 
normal testicular tissue, are loaded with the MC2R (40). The 
close phenotype shared by TART and fetal adrenals, includ-
ing classical markers of adrenal steroidogenesis, highly favors 
the hypothesis that TART develops from an original adrenal 
cortical cell type.
 – In Cushing’s disease patients, particularly those treated by 
“total” bilateral adrenalectomy, a large increase in ACTH 
secretion can be triggered. It may play a role in the growth 
of adrenal rests, locally (adrenal extrusions that have escaped 
the surgeon tools!), but also at distance, in the testis, and many 
other places (41, 42).
RARe AnD PARTiCUlAR SiTUATiOnS
Mimicking Chronic ACTH excess
There are several pathological conditions where pituitary ACTH 
is actually suppressed and cortisol is oversecreted in response to 
molecular phenomenon which occur directly at the adrenal level, 
and, somehow, mimick chronic ACTH excess:
 – ACTH may be produced locally by tumoral adrenal cells, and 
its autocrine action may participate in cortisol oversecretions 
in cases of bilateral macronodular adrenal hyperplasia (43).
 – In the absence of ACTH, its signaling pathway may be nev-
ertheless overactivated and generate excess of corticosteroid 
secretion: adrenocortical tumors which express illegitimate 
G-protein coupled receptors (44, 45), activated mutated 
MC2R (46), mutated PRKAR1A in the Carney complex (47, 
48), and mutated PKACa in adrenocortical adenomas (49).
 – It has also been suggested auto antibodies acting at the ACTH 
receptor might be responsible for excess cortisol secretion in 
some cases of Wulffraat (50). Yet little confirmation has been 
obtained since the original paper.
It is interesting to observe that all these situations eventually 
result in the overactivation of the cAMP signaling pathway, 
and always occur in benign tumors. They concur with the idea 
that chronic ACTH excess, or chronic activation of its signaling 
pathway at the same time may have some growth effect but also 
a differentiation action.
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when “normal” ACTH is Too Much!
In the syndrome of apparent mineralocorticoid excess, the loss of 
function of 11 hydroxysteroid dehydrogenase type II, particularly 
at the kidney, locally enhances the mineralocorticoid action of 
cortisol (51).
In the glucocorticoid-remediable aldosteronism, gene rear-
rangement induces the “ectopic” expression of the Aldo synthase 
gene within the ZF cells and thus provokes the oversecretion of 
aldosterone under the action of ACTH (52).
In these two situations, the HPA axis and cortisol secretion 
are normal. Yet, it drives a state of “apparent” or “real” mineralo-
corticoid excess, and the treatment option is indeed to suppress 
ACTH secretion.
non-ACTH POMC Peptides
As mentioned earlier, ACTH is part of a larger polypeptide 
precursor, POMC the enzymatic processing of which liberates 
ACTH itself and a number of other “non-ACTH” POMC-derived 
peptides. Among these peptides, the lipotropins (beta- and 
gamma-lipotropins) exert a definitive action on the melanocytes 
in man, and are responsible, together with ACTH, for skin 
hyperpigmentation that is observed in all situations of excess 
endogenous ACTH secretion. Beta-endorphin is an opioid 
peptide, which is a processing product of POMC. It circulates in 
blood, in parallel with the ACTH that is secreted by normal or 
tumoral pituitary or non-pituitary corticotroph cells. Yet, even at 
extremely high plasma values, circulating beta-endorphin has no 
known actions in man, and does not exert any analgesic action 
(53). The analgesic effect of beta-endorphin is entirely due to 
that which is produced locally in the brain by a set of POMC-
expressing neurons: the circulating beta-endorphin does not 
cross the blood–brain barrier.
Experimental evidence suggest that non-ACTH N-terminal 
POMC peptides may exert a growth effect on the adrenal cortex 
(54, 55). The small peptide N-POMC1–28, which bears two intra-
molecular disulfide bridges, is responsible for this action which 
has also been described in the human adreno cortical tumors cells 
NCI-H295 (56). Yet the receptor for the N-POMC1–28 peptide 
remains elusive (55).
Chronic Stress and Pseudo-Cushing
Pseudo-Cushing corresponds to these situations in man where an 
authentic hypercortisolism is biologically present (increased uri-
nary cortisol, abnormal response to dexamethasone suppression 
test) and may be confused with “endogenous” Cushing’s disease. 
Yet, in Pseudo-Cushing there is no pituitary adenoma; the ACTH 
excess is thought to be “functional,” driven by the overactivity of 
the hypothalamus and oversecretion of corticotrophin-releasing 
hormone under chronic stress, severe depression, intense physi-
cal activity, and anorexia nervosa (57).
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